Dr. Brian G. Feagan, at the University of Western Ontario in London, and colleagues conducted the randomized, double-blind, placebo-controlled trials at sites in Canada, the U.S., Europe and Israel. Study subjects were patients with Crohn disease in remission.
Active treatment comprised four daily 1g delayed-release soft gelatin capsules of omega-3 free fatty acids (Epanova), consisting of 50-60% eicosapentaenoic acid and 15-25% docosahexanoic acid. The placebo capsules contained 1g of medium-chain triglyceride oil.